EBITDA

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

Beyond vaccines, Strand Therapeutics' programmable mRNA shows stunning success in late-stage cancer, heralding a new age of logic-driven genetic medicine.

NAVEE launches its rugged XT5 Pro scooter, challenging off-road rivals with a blend of high-performance tech, certified safety, and eco-friendly power.

The hiring of M&A veteran Eric Olson as Chief Corporate Development Officer signals REI Systems’ aggressive new strategy to conquer the national security market.

A fintech firm's new hire seems distant, but it signals a crucial shift in how capital flows into life-saving research and healthcare innovation.

As Natuzzi prepares its Q3 results, the luxury furniture maker's costly bet on Italian craftsmanship faces a critical test amid a tough economy.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

MCF Advisors' acquisition of AWM, its first since a major PE investment, pushes its AUM to $3.9B and showcases the playbook reshaping regional wealth.

Quipt Home Medical's acquisition by private equity offers a massive premium to shareholders and sets the stage for aggressive M&A in the home respiratory care market.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

Beyond software, a new accelerator offers hardware startups a rare advantage, bridging the gap from university labs to investor-ready prototypes.

A landmark green ammonia project in Spain offers a blueprint for industrial decarbonization, holding key strategic lessons for the biopharmaceutical sector.

A complex share buyback and reverse stock split reveal Havas's deeper strategy: shoring up its finances to invest in a new era of health communication.

A new AI system deters birds to prevent avian flu. But its real innovation lies in data, transforming biosecurity from a costly chore into a profitable investment.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.